Carsten Lukas

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

Sven Jarius, Klemens Ruprecht, Ingo Kleiter et al. · Journal of Neuroinflammation · 2016 · 891 citations · Full text

Medicine, Neurology, Neuroscience +15

Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism

Alexander Duscha, Barbara Gisevius, Sarah Hirschberg et al. · Cell · 2020 · 630 citations · Full text

Life Sciences, Immunology, Neurology +16

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome

Sven Jarius, Ingo Kleiter, Klemens Ruprecht et al. · Journal of Neuroinflammation · 2016 · 250 citations · Full text

Medicine, Neurology, Neuroscience +17

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot study

Sebastian Schimrigk, N. Brune, Kerstin Hellwig et al. · European Journal of Neurology · 2006 · 219 citations

Pharmacy, Neurology, Pharmacotherapy +14

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

Martin Stangel, Iris‐Katharina Penner, Boris Kallmann et al. · Therapeutic Advances in Neurological Disorders · 2014 · 168 citations · Full text

Medicine, Neurology, Cognitive Neurology +15